News
Bellvitge Hospital, IDIBELL and Astrazeneca test an application that monitors heart failure using voice
Through a mobile device, HearO™ makes it possible to predict possible complications in patients with heart failure through speech, detect disease-related fluid accumulation and alert the doctor before hospitalization
Research team from IDIBELL and UB find that HERC1 protein deficiency causes osteopenia
Scientists from IDIBELL and the University of Barcelona identify how HERC1 deficiency unbalances bone homeostasis, causing osteopenia. These results identify potential therapeutic targets for individuals with bone diseases and HERC1 deficiency.
New evidence for the correct detection of oropharyngeal cancers caused by the human papillomavirus
To establish whether oropharyngeal cancer was related to the human papillomavirus, the recomendation is do it through the p16 protein detection.
Now a study from IDIBELL published in The Lancet Oncology has shown that not all p16-positive oropharyngeal cancers are caused by the virus.
An investigation by HUB and IDIBELL shows the adaptation of bacteria in COPD patients and prolonged treatment with azithromycin
The IDIBELL Bacterial Epidemiology research group has published a paper on the adaptation of Haemophilus spp in patients with chronic obstructive pulmonary disease (COPD) and prolonged treatment with azithromycin.
Association between polyphenols from diet and body weight change
The results, published in Antioxidant and Obesity scientific journals, show that the intake of most polyphenols is associated with maintenance or a lower weight gain, highlighting those polyphenols present in fruits, vegetables, olive oil, tea, cocoa, or cereals integral.
Jut Against Cancer Association donates 6,000 euros to pancreatic cancer research
The Association Jut against cancer is a recently created association from Sant Boi de Llobregat that raises funds through different solidarity, sporting and creative initiatives in which the patients participate.
A drug that prevents DNA reparation could improve the survival of patients with one of the most aggressive prostate cancers
The results of the TRITON3 study show that patients with prostate cancer treated with a PARP inhibitor, called Rucaparib, take almost twice as long for the disease to progress than those treated with conventional chemotherapy.
The Govern awards the Josep Trueta plaque for health merit to the Hospital de Bellvitge
The Govern approved today the awarding of the Josep Trueta medals and plaques to outstanding professionals and entities in the health field. Among the award-winning entities is the Bellvitge University Hospital, for its work as a reference center of maximum complexity for 2 million people. Likewise, one of the individual medals has been for Dr. Mònica Povedano, a neurologist at Hospital de Bellvitge and IDIBELL researcher.
The diagnosis and treatment of glioblastoma during the 2008 financial crisis and the COVID-19 pandemic
The availability and ease of resources, and the time between the appearance of the primary tumor and the start of treatment are key to the patient’s prognosis, already poor in this disease.